Baekkeskov, SteinunnHubbell, Jeffrey A.Phelps, Edward A.2017-10-092017-10-092017-10-09201710.1016/j.addr.2017.06.007https://infoscience.epfl.ch/handle/20.500.14299/141135WOS:000411420400019Type 1 diabetes is an autoimmune disease marked by the destruction of insulin-producing beta cells in the pancreatic islets. Strategies to delay onset or prevent the autoimmune recognition of beta cell antigens or T cell-mediated killing of beta cells have mainly focused on systemic immunomodulation and antigen-specific immunotherapy. To bridge the fields of type 1 diabetes immunology and biomaterials engineering, this article will review recent trends in the etiology of type 1 diabetes immunopathology and will focus on the contributions of emerging bioengineered strategies in the fight against beta cell autoimmunity in type 1 diabetes. (C) 2017 Elsevier B.V. All rights reserved.Type 1 diabetesAutoimmunityToleranceBiomaterialstext::journal::journal article::review article